Poster Abstract Session:
239. HIV and Viral Hepatitis Co-Infection
Saturday, October 6, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall

Tracks: Adult ID, HIV-STD-TB, Pediatric ID

Long-term Immunogenicity of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: An extension of a randomized controlled trial
Romanee Chaiwarith, MD; Jutarat Praparattanapan, PhD; Jiraprapa Wipasa, PhD; Kanokporn Chaiklang, MD; Khuanchai Supparatpinyo, MD
Zinc deficiency and advanced liver fibrosis among HIV/HCV co-infected persons in Russia
Joshua Barocas, MD; Kaku So-Armah, PhD; Debbie Cheng, PhD; Dmitry Lioznov, MD; Marianna Baum, PhD, MS; Kerrin Gallagher, MS; Daniel Fuster, MD; Natalia Gnatienko, MS; Evgeny Krupitsky, MD; Matthew Freiberg, MD, MSc; Jeffrey Samet, MD, MPH
  • Barocas_IDWeek_poster.pdf (500.2 kB)
  • Hepatitis C Eradication: Who is being left behind in the HIV population?
    Mamta K Jain, MD, MPH; Claudia Chavez, B.S.; Joanne Sanders, MS; Kranthi Vysyaraju, MS
    Implementing a Co-located HCV Clinic within an HIV Clinic: Four Year Experience
    Merceditas Villanueva, MD; Christina Rizk, MSc.; Bethel Shiferaw, MD; Onyema Ogbuagu, MD, FACP; Maricar Malinis, MD, FACP, FIDSA; Janet Miceli, MPH
    A Collaborative Drug Therapy Management Model for the Treatment of Hepatitis C Virus (HCV) in an Urban Clinic
    Sonia Vibhakar, PharmD; Diana Nowicki, PharmD; Greg Huhn, MD; Rebecca Goldberg, RN; Oluwatoyin Adeyemi, MD
    Direct-Acting Antivirals: Efficacy in a Real-World, Urban, Undeserved, HIV-HCV Co-Infected Population
    Sarah Michienzi, PharmD, BCPS, AAHIVP; Rodrigo Burgos, PharmD, AAHIVP; Renata Smith, PharmD, AAHIVP; Michelle Martin, PharmD, PharmD, FCCP, BCPS, BCACP
    Validity of Self-Reported HCV Status among Justice-Involved Persons Living with HIV
    Amanda Noska, MD, MPH; Tao Liu, MS; Irene Kuo, PhD, MPH; Mia Coetzer, PhD; Ann Kurth, PhD, MPH; Rami Kantor, MD; Curt Beckwith, MD

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.